pharmaceutical-investing Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality - Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026
pharmaceutical-investing Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors
pharmaceutical-investing Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
pharmaceutical-investing Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved
pharmaceutical-investing Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results
Benz Announces that Icon Delivers Shallow High-Grade Discovery as Large-Scale System Continues to Grow
Benz Announces that Icon Delivers Shallow High-Grade Discovery as Large-Scale System Continues to Grow
